BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 26, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Nypta tideglusib: Phase IIa data

Noscira S.A., Madrid, Spain
Product: Nypta tideglusib ( NP-12)
Business: Neurology
Molecular target: Glycogen dependent kinase 3 (GSK3)
Description: 1,2,4-thiadiazolidine-3,5-dione derivate and glycogen dependent kinase 3 (GSK3) inhibitor
Indication: Treat Alzheimer's disease
Endpoint: Safety
Status: Phase IIa data...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >